the current status of pi3k inhibitors in hematological malignancies and challenges to overcome
Published 1 year ago • 151 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:34
the promise of second-generation pi3k inhibitors for cll
-
0:16
label-free live cell imaging: activated t-cell killing cancer cell
-
2:44
phase i/ii study of novel flt3 inhibitor hm43239 in r/r aml
-
3:03
prognostic impact of flt3-itd in older patients with aml
-
1:59
tangible benefit for flt3-itd r/r aml on quizartinib
-
7:22
biology: cell structure i nucleus medical media
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
4:21
pi3k akt mtor pathway (and the effects)
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
2:54
quantum-first: association between flt3-itd-specific mrd clearance and survival in patients with aml
-
1:55
assessing flt3-itd-specific mrd clearance using a pcr-ngs assay in the quantum-first trial
-
1:35
redirect results: afm13 in patients with cd30 r/r ptcl
-
3:39
role of pi3k inhibitors in hr metastatic breast cancer
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
3:21
the prognostic impact of flt3-itd and flt3-tkd in npm1-mutated aml
-
3:04
ff-10101-01: a novel flt3 inhibitor for r/r aml
-
6:44
pi3k/akt pathway - part 1: overview
-
7:49
pi3k inhibitors data review: how do they compare with cdk4/6 inhibitors, mtor inhibitors, ais and ot